- Catalyst Biosciences Names Andrew Hetherington as Vice President of Manufacturing Operations– click to read
- Catalyst Biosciences, Inc. to Present at the Rodman & Renshaw 17th Annual Global Investment Conference– click to read
- Catalyst Biosciences Completes Merger With Targacept and Creates a Protease-Based Hemostasis and Anti-Complement Company– click to read
Next Generation Hemostasis Programs
Our most advanced program is focused on the treatment of hemophilia and surgical bleeding using our potent, long acting variants of proteases that promote blood clotting.
Anti- Complement Programs
Our second area of focus is regulation of the complement cascade, a series of molecular processes that plays a central role in the body’s inflammatory and immune responses.
The Catalyst Advantage
Drug candidates for severe medical conditions
Learn more about the medicines we are developing.
Our unique and proprietary science
Understand our science.
Addressing diseases with unmet medical needs
Share our passion about treating disease.
We have an experienced and passionate team
Learn more about the Catalyst team and mission/culture.